These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16334120)

  • 1. Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen.
    Mielke S; Sparreboom A; Behringer D; Mross K
    Anticancer Res; 2005; 25(6C):4423-7. PubMed ID: 16334120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
    Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
    Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
    Miller AA; Rosner GL; Egorin MJ; Hollis D; Lichtman SM; Ratain MJ
    Clin Cancer Res; 2004 Dec; 10(24):8325-31. PubMed ID: 15623609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
    Gelderblom H; Mross K; ten Tije AJ; Behringer D; Mielke S; van Zomeren DM; Verweij J; Sparreboom A
    J Clin Oncol; 2002 Jan; 20(2):574-81. PubMed ID: 11786588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
    Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
    Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
    Panday VR; ten Bokkel Huinink WW; Vermorken JB; Rosing H; Koopman FJ; Swart M; Schellens JH; Beijnen JH
    Pharmacol Res; 1999 Jul; 40(1):67-74. PubMed ID: 10378993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
    Johnson DH; Paul DM; Hande KR; DeVore R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring of paclitaxel (Zisu) in cancer patients.
    Wu D; Liang Y; Liu Q
    J Environ Pathol Toxicol Oncol; 2000; 19(1-2):77-80. PubMed ID: 10905511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
    Ceresoli GL; Gregorc V; Cordio S; Bencardino KB; Schipani S; Cozzarini C; Bordonaro R; Villa E
    Lung Cancer; 2004 May; 44(2):231-9. PubMed ID: 15084388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue?
    Pace A; Nisticò C; Cuppone F; Bria E; Galiè E; Graziano G; Natoli G; Sperduti I; Jandolo B; Calabretta F; Tomao S; Terzoli E
    Clin Breast Cancer; 2007 Apr; 7(7):550-4. PubMed ID: 17509163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients.
    Grau JJ; Caballero M; Verger E; Monzó M; Blanch JL
    Acta Otolaryngol; 2009 Nov; 129(11):1294-9. PubMed ID: 19863327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma.
    Higashiyama T; Ito Y; Hirokawa M; Fukushima M; Uruno T; Miya A; Matsuzuka F; Miyauchi A
    Thyroid; 2010 Jan; 20(1):7-14. PubMed ID: 20025538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan.
    Horiguchi J; Rai Y; Tamura K; Taki T; Hisamatsu K; Ito Y; Seriu T; Tajima T
    Anticancer Res; 2009 Feb; 29(2):625-30. PubMed ID: 19331212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
    Ohtsu T; Sasaki Y; Tamura T; Miyata Y; Nakanomyo H; Nishiwaki Y; Saijo N
    Clin Cancer Res; 1995 Jun; 1(6):599-606. PubMed ID: 9816021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
    Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
    Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
    Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
    Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1035-48. PubMed ID: 18791717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.